metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
versus trastuzumab
	pertuzumab plus trastuzumab
	PERTAIN, 2018 J Clin Oncol 2018; 36:2826-2835-. NCT01491737	RCT	la/mBC - HER2 positive - 1st Line (L1)	pertuzumab plus trastuzumab plus an AI (letrozole or anastrozole)	trastuzumab plus an AI (letrozole or anastrozole)	Postmenopausal patients, with first-line HER2-positive and HR positive disease	129 / 129	NA	conclusif	demonstrated 35 % decrease in progression or deaths (PFS) (PE)
versus trastuzumab plus chemotherapy
	trastuzumab plus endocrine therapy
	SYSUCC-002, 2022 Clin Cancer Res 2022; 28:637-645-. NCT01950182	RCT	la/mBC - HER2 positive - 1st Line (L1), la/mBC - HR-positive - 1st line (L1)	trastuzumab plus endocrine therapy	trastuzumab plus chemotherapy	Female patients aged of 18 or more, with locally histology confirmed mBC, HR-positive (ER and/or PR-positive) and HER2-positive	196 / 196	some concern	inconclusive	inconclusive 12 % decrease in progression or deaths (PFS) (PE)
versus trastuzumab plus docetaxel
	bevacizumab plus trastuzumab plus docetaxel
	AVEREL, 2013 J Clin Oncol 2013; 31:1719-25-. NCT00391092	RCT	la/mBC - HER2 positive - 1st Line (L1)	bevacizumab plus docetaxel plus trastuzumab	docetaxel plus trastuzumab	Patients with HER2-positive measurable or evaluable locally recurrent or metastatic BC, ad received no prior trastuzumab or chemotherapy for LR/MBC	216 / 208	some concern	inconclusive	inconclusive 18 % decrease in progression or deaths (PFS) (PE)
	pertuzumab plus trastuzumab plus docetaxel
	PUFFIN, 2020 Breast Cancer Res Treat 2020; 182:689-697-. NCT02896855	RCT	la/mBC - HER2 positive - 1st Line (L1)	pertuzumab plus trastuzumab plus docetaxel	placebo plus trastuzumab plus docetaxel	Patients with HER2-positive, locally recurrent or metastatic BC, no prior therapy for metastatic disease, 18yr or older.	-/-	NA	suggested	suggested 31 % decrease in progression or deaths (PFS)
	CLEOPATRA, 2012 Lancet Oncol 2020; 21:519-530-. Lancet Oncol 2013; 14:461-71-. N Engl J Med 2015; 372:724-34-. N Engl J Med 2012; 366:109-19-. Breast Cancer Res Treat 2013; 142:89-99-. Ann Oncol 2017; 28:2761-2767-. NCT00567190	RCT	la/mBC - HER2 positive - 1st Line (L1)	pertuzumab plus trastuzumab plus docetaxel	placebo plus trastuzumab plus docetaxel	Patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer who had not received chemotherapy or biologic therapy for their metastatic disease. They may have received one hormonal treatment for metastatic breast cancer before randomization, and/or adjuvant or neoadjuvant chemotherapy with or without trastuzumab before randomization	402 / 406	low	conclusif	demonstrated 34 % decrease in deaths (OS) (PE) demonstrated 38 % decrease in progression or deaths (PFS) (PE) suggested 31 % decrease in deaths (OS) (extension) suggested 31 % decrease in PFS (extension) more...